142 related articles for article (PubMed ID: 25268070)
1. Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Choi GH; Han S; Shim JH; Ryu MH; Ryoo BY; Kang YK; Kim KM; Lim YS; Lee HC
Am J Clin Oncol; 2017 Apr; 40(2):167-174. PubMed ID: 25268070
[TBL] [Abstract][Full Text] [Related]
2. Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
Yoo JJ; Chung GE; Lee JH; Nam JY; Chang Y; Lee JM; Lee DH; Kim HY; Cho EJ; Yu SJ; Kim YJ; Yoon JH;
Cancer Res Treat; 2018 Apr; 50(2):366-373. PubMed ID: 28521494
[TBL] [Abstract][Full Text] [Related]
3. Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
Kim HY; Lee DH; Lee JH; Cho YY; Cho EJ; Yu SJ; Kim YJ; Yoon JH
BMC Cancer; 2018 Mar; 18(1):307. PubMed ID: 29558905
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
5. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
6. Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2016 Apr; 34(2):255-60. PubMed ID: 26769245
[TBL] [Abstract][Full Text] [Related]
7. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Inoue M; Wakamatsu T; Tawada A; Yokosuka O
PLoS One; 2016; 11(8):e0161303. PubMed ID: 27537374
[TBL] [Abstract][Full Text] [Related]
9. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
11. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Diaz-Beveridge R; Bruixola G; Lorente D; Caballero J; Rodrigo E; Segura Á; Akhoundova D; Giménez A; Aparicio J
Clin Transl Oncol; 2018 Mar; 20(3):322-329. PubMed ID: 28801777
[TBL] [Abstract][Full Text] [Related]
12. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
Li MX; Zhao H; Bi XY; Li ZY; Yao XS; Li H; Huang Z; Han Y; Zhou JG; Zhao JJ; Zhang YF; Zhao DB; Cai JQ
Oncotarget; 2016 Dec; 7(52):86630-86647. PubMed ID: 27880930
[TBL] [Abstract][Full Text] [Related]
13. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
16. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
17. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Yoon EL; Yeon JE; Ko E; Lee HJ; Je JH; Yoo YJ; Kang SH; Suh SJ; Kim JH; Seo YS; Yim HJ; Byun KS
J Korean Med Sci; 2017 Feb; 32(2):212-220. PubMed ID: 28049231
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
Okuyama H; Ikeda M; Kuwahara A; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Senda S; Okusaka T
Oncology; 2015; 88(4):241-6. PubMed ID: 25503567
[TBL] [Abstract][Full Text] [Related]
20. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
Sarpel U; Spivack JH; Berger Y; Heskel M; Aycart SN; Sweeney R; Edwards MP; Labow DM; Kim E
HPB (Oxford); 2016 May; 18(5):411-8. PubMed ID: 27154804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
